Skip to main content
RHYTHM PHARMACEUTICALS, INC. logo

RHYTHM PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · RYTM ISIN · US76243J1051 LEI · 529900JPNWXQ8DPLA551 US Manufacturing
Filings indexed 775 across all filing types
Latest filing 2023-06-21 Director's Dealing
Country US United States of America
Listing US RYTM

About RHYTHM PHARMACEUTICALS, INC.

https://rhythmtx.com/

Rhythm Pharmaceuticals is a global, commercial-stage biopharmaceutical company focused on developing and commercializing precision medicines for rare genetic diseases of obesity. The company's work centers on the melanocortin-4 receptor (MC4R) pathway, a key biological system that regulates hunger and energy expenditure. Its lead product, IMCIVREE® (setmelanotide), is an MC4R agonist approved for treating severe obesity and hyperphagia (insatiable hunger) in patients with specific rare conditions, such as Bardet-Biedl syndrome. Rhythm is dedicated to advancing a portfolio of therapies that address the root cause of rare neuroendocrine diseases to improve patient outcomes.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2023-06-21 English
10-Q
Interim / Quarterly Report Q1 2023
2023-05-02 English
FORM 8-K
Regulatory Filings
2023-05-02 English
DEFA14A
Regulatory Filings
2023-04-27 English
DEF 14A
Proxy Solicitation & Information Statement
2023-04-27 English
ARS
Annual Report
2023-04-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.